




Supplemental Figure S1: Representative images show different types of renal cells in the urine. L1-Cam is collecting duct cell (CDC) marker, CD13 and LTA are proximal tubule cell (PTC) markers. THP is a thick ascending limb marker. NCC is distal tubule cell marker. Scale bar=10 μ m



Supplemental Figure S2: α ENaC, β ENaC and γ ENaC staining in permeabilized urine-derived renal tubule cells. Nuclei are in blue. α ENaC, β ENaC and γ ENaC are in green. CD13 is in red. Scale bar =10 μ m




Supplemental Figure S3. α ENaC, β ENaC and γ ENaC (StressMarq antibodies) staining in human renal cortex. Both α ENaC and β ENaC are present in PTC. γ ENaC is restricted within CDCs. α ENaC, β ENaC and γ ENaC are in red. LTA, a PTC marker, is in green. L1-CAM, a CDC marker, is in blue. Rb (rabbit) IgG and no primary antibody are tested as negative controls. The lower panel of (A) is zoomed-in views of boxed regions of the upper panel. Scale bar = 10 μ m




Supplemental Figure S4: α ENaC was stained in cells digested from fresh human renal cortex in suspension. Rabbit IgG was used for negative control. CD13 positive cells also shows strong α ENaC staining on their apical side. Scale bar = 10 μ m


A




B



Supplemental Figure S5. αENaC western blot analysis in more urine-derived hRTC lines. (A) αENaC western blot in another 15 urine-derived hRTC lines. SR, salt resistant, SS salt sensitive; ISS inverse salt sensitive. The calculation was normalized by SR1 on each blot. (B) αENaC level in different genotype. Homozygous major variants are in orange; heterozygous samples are in green; homozygous minor variants are in purple.



Supplemental Figure S6: βENaC and γENaC are found in CD13^+ urine-derived hRHCs. Actin was used as loading control in all western blot analysis. A and B) There is no significant difference of βENaC among different phenotypes. C and D) γENaC is significantly higher in SS than both SR and ISS.



Supplemental Figure S7. Representative images of mineralocorticoid receptor (MR) and α ENaC immunostaining under aldosterone treatment. MR staining is in green (A), and α ENaC is stained in red (B). Scale bar = 200 μ m

Supplemental Table S1**Characteristics of UVA Study Subjects (Mean±SD)**

	Inverse Salt Sensitive Subjects	Salt Resistant Subjects	Salt Sensitive Subjects	P Value
Number of subjects	37	178	65	
Male	12	78	23	0.2837 ⁺
Female	25	100	42	
Age (yrs)	40.8±15.2	42±15.1	50.5±14.2	0.0002
BMI	25.1±3.0	24.8±2.9	25.3±2.9	0.4716
<u>After Low Sat Diet</u>				
Systolic (mmHg)	121±13.3	117.2±13.8	114.9±12.7	0.0915
Diastolic (mmHg)	76.2±8.4	72.9±9.1	71.7±6.5	0.0345
MAP (mmHg)	91.1±9.5	87.7±10	86.1±7.8	0.0382
<u>After High Sat Diet</u>				
Systolic (mmHg)	110.3±12.2	118.5±14.1	129.5±12.9	<0.0001
Diastolic (mmHg)	66±7.3	71.9±9.6	80±8.2	<0.0001
MAP (mmHg)	80.7±8.6	87.4±10.5	87.4±10.5	0.0013

For the continuous variables, one-way ANOVA was used to compare the three groups.

+ Comparison of distribution of gender in three groups was done by Chi-square test.

Supplemental Table S2: Odds Ratio

	ISS	NON-ISS (SR+SS)
SNPed (Homozygous minor variant and heterozygous)	23	112
NON-SNPed (homozygous major variant)	14	130

Odds ratio = $23 \times 130 / (14 \times 112) = 1.91$, indicating the odds are 1.91 times higher that people who have rs4764586 will become ISS compare to those who are homozygous major variant.